# Stakeholders' experiences of HIV patient engagement within the I-Score patient patient - reported outcomes Research and Evaluation (CRES)/2 with thin the I-Score patient patient - reported outcomes Research and Evaluation (CRES)/2 with the for Outcomes Research and Evaluation (CRES)/2 with the format of the control of the cont

benefits and challenges

**McGill** 

SPOR\*SRAP



Lessard  $D^{1,3,4,5}$ , Engler  $K^{1,3,5}$ , Vicente  $S^{1,2,5}$ , Toupin  $I^{1,3,4,5}$ ; Cox  $J^{1,3}$ ; Kronfli  $N^{1,3}$ ; Routy  $JP^{1,3}$ ; Lebouché  $B^{1,3,4,5}$ 

1. McGill University Health Centre Centre for Outcomes Research and Evaluation, Montreal, Canada; 2. University of Montreal Department of Mathematics and Statistics, Montreal, Canada; 3. McGill University Health Centre Chronic Viral Illness Service, Montreal, Canada; 4. McGill University Department of Family Medicine, Montreal, Canada; 5. Canadian Institutes of Health Research Strategy for Patient-Oriented Research Menroship Chair in Innovative Clinical Trials, Montreal, Canada



# Introduction

Patient engagement (PE) in research is recognized as a valuable approach to improve the quality, applicability, and relevance of health research and its benefits for accountable and accessible healthcare<sup>1,2</sup>. PE implies, in part, partnerships and mentorship between multidisciplinary investigators and patients, given the importance and complementarity of their respective perspectives.

However, how different stakeholders experience these partnerships and how these experiences evolve, is little documented<sup>3,4</sup>.

Aim: To address this gap by presenting three stakeholders' perspectives on their experience of PE

# The I-Score Study and Patient Engagement (PE)

5 men:

PE was integrated in the I-Score Study through the I-Score Consulting Team and its activities.

#### The I-Score Study

**Objective:** to develop and validate the clinical use of a digital HIV-specific patient-reported outcome measure of antiretroviral therapy adherence barriers.

So far, work on the **conceptual framework** included:

- a synthesis of qualitative studies on adherence barriers to antiretroviral therapy
  - 27 semi-structured interviews with PLHIV.

A **Delphi** will be conducted to translate and adapt the conceptual framework for PLHIV, clinicians, and other relevant stakeholders,

An adaptive trial will evaluate how the implementation of the I-Score measure into HIV care.

# The I-Score Consulting Team

- was formed by a **PE coordinator**
- initially a group of ten diverse people living with HIV (PLHIV) living in Montreal, Canada

(one anglophone; one European) 1 African MSW

**4 White MSM** 

5 women:

2 White WSM (one anglophone; one ex-IDU) 3 African women

Members' age: between 28 and 55 years old. Number of years on ART : < 3 years to > 10 years.

- is engaged in **each step of the I-Score Study** by holding meetings to discuss its advancements
- collaborates in knowledge-transfer activities (KTAs) to disseminate results to concerned communities
- is involved as participants in research concerned with the patient perspective and the evaluation of PE in the I-Score Study

## **Materials and Methods**

The table below presents the experiences of PE of three distinct types of stakeholders who participated in the I-Score Study: 1) clinical investigators 2) a PE coordinator 3) a patient-investigator

Using a reflexive and deliberative exercise, stakeholders identified the challenges they encountered while implementing and pursuing PE in the context of the I-Score Study and their implications

# Results: Stakeholders' challenges and solutions at three key moments of the Patient Engagement Project

feedback

investigators

input integration

Consulting Team

clinical research

# Moments of the PE project

#### Stakeholders

## Investigators

Role: conduct of the I-Score Study

PE coordinator

activities, and liaison between

Role: organization of PE

the Consulting Team and

**I-Score investigators** 

# **Initiation of PE**

Project design, recruitment of patients

Challenge: Facing the possibility of limited patient interest in the PE Project

Solution: Deciding to play it by ear

Challenge: Understanding the boundaries between PE and research, for example, given overlap in methods

Solution: Making provisions in the protocol for engaged patients to also be participants in I-Score-related research

#### Challenge: Deciding who we should recruit

for example, research experience, community involvement,

**Challenge:** Determining how to evaluate the PE Project

**Solution:** Using a convergent mixed method design and

# **Patient-investigator**

Role: provision of patient and academic/scientific expertise through involvement in PE activities (patient Team meetings) and research

Solution: Using maximum variation sampling, considering, and the main groups affected by HIV in Quebec:

involving PE Project participants

### Challenge: Managing a recent HIV diagnosis and its consequences, including difficulty accessing medication, depression, feeling useless as a PLHIV, and confidentiality

issues with a group of investigators and other PLHIV

Challenge: Feeling demotivated with academic life **Solution:** Seeking opportunities in the PE Project to share

academic expertise

# **Solution:** Getting involved in the PE Project to discuss these

Challenge: Not wanting to be a 'passive' member of the

**Consulting Team** 

complexity of the patient perspective

for its members as possible

**Solution:** Taking on a 'hybrid' patient-investigator role

Implementation of PE

**Conducting Consulting Team meetings and** 

integration with I-Score Study

Challenge: Determining what patient input can/cannot do

**Solution:** Considering multiple sources of input in research

decision-making (e.g., research evidence, engaged patients'

**Solution:** Communication between investigators and PE

to investigators, given multiple view points within the

**Solution:** Attending to engaged patients' preferences

coordinator to clarify perspectives on the timeline of patient

Challenge: Having difficulty reporting the 'patient perspective'

Solution: Meeting regularly with investigators to convey the

Challenge: Making the Consulting Team's engagement as easy

Challenge: Not seeing the value of the patient perspective to

**Solution:** Participating regardless, and gradually realizing its

Challenge: Tension with the PE coordinator around the urgency

to see concrete use of patient input and the perceived inaction of

# **Expansion of PE**

Integration of PE in all research projects affiliated with a Mentorship Chair in innovative clinical trials (awarded to BL by the Canadian Insitutes of Health Research)

Challenge: Negative (and positive) impacts on the study timeline and budget, as PE becomes a necessary component of research

Solution: Finding ways to compensate /catch up, seeking additional funding

Challenge: Ensuring transparency and documentation of how patient input is used or not in practice Solution: Formalizing the process of receiving and responding to patient feedback within the Mentorship Chair

**Challenge:** Having a heavier workload due to increasing demand to engage patients in new projects

**Solution:** Drawing on previously gained experience and skills

**Challenge:** Fearing that PE in the new projects may become less meaningful

**Solution:** Clarifying with interested investigators their expectations of PE and guiding them, as necessary

Challenge: Juggling PE, academic research, and professional life

**Solution:** Establishing priorities

#### Conclusion

value

Through PE with PLHIV, stakeholders affiliated with the I-Score Study faced unanticipated personal and professional impacts, illustrating PE's potential to challenge and change existing research practices and experiences of living with HIV. Despite initial doubts and lack of experience with the integration of patient expertise in research, PE has become an unavoidable and key component of investigators' research activities.

**ACKNOWLEDGMENTS**: DL and IT are postdoctoral trainees of a Strategy for Patient-Oriented Research (SPOR) Mentorship Chair in Innovative Clinical Trials awarded by the Canadian Institutes of Health Research (CIHR) (www.cihr-irsc.gc.ca) to BL (#383427). DL and IT were supported by Mitacs through the Mitacs-Accelerate Program (#IT05857), DL received an Quebec Health Research Funds (FRQ-S) (#28899). Partial funding for the I-Score Study was received from the CIHR's HIV Clinical Trials Network (CTN 283), from the Quebec SPOR Support Unit (M606), and from a research grant from the Investigator Initiated Studies Program of Merck Canada Inc. (IISP-53538). The Patient Engagement Project is supported by an unrestrictive grant from Gilead Sciences Canada Inc. The opinions expressed in this manuscript are those of the authors and do not necessarily represent those of Merck Canada Inc., Gilead Sciences Canada Inc., or their affiliates or related

# **REFERENCES**

(1) CIHR. Patient Engagement 2014. <a href="http://www.cihr-irsc.gc.ca/e/45851.html">http://www.cihr-irsc.gc.ca/e/45851.html</a>.

Interdisciplinary Postdoctoral Award of the Health Research Foundation, and BL by a clinician-researcher award of the (2) Concannon et al. A systematic review of stakeholder engagement in comparative effectiveness and patient-centered outcomes research. J Gen Intern Med. 2014. (3) Oliver et al. A multidimensional conceptual framework for analysing public involvement in health services research. Health Expectations. 2008.

(4) Esmail et al. Evaluating patient and stakeholder engagement in research: moving from theory to practice. Journal of Comparative Effectiveness Research. 2015.





